Hyperinflammation and Hyperferritinemia in Critically Ill Patients
Launched by CHARLES UNIVERSITY, CZECH REPUBLIC · Feb 6, 2025
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how critically ill patients, especially those with conditions like severe infections and high levels of a protein called ferritin, respond to their illness. Researchers are particularly interested in patients who show signs of a strong inflammatory response, known as hyperinflammation. The goal is to learn more about the course of their illness and how best to support their recovery.
To be eligible for this study, participants must be critically ill and admitted to a hospital between January 1, 2020, and December 31, 2024. There are no specific exclusions, meaning anyone who meets the inclusion criteria can potentially participate. If you or a loved one is eligible, participating in this trial can help researchers gather important information that may improve treatment for future patients facing similar health challenges. Please note that the trial is not yet recruiting participants, but it represents an opportunity to contribute to medical knowledge in the field of critical care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • critically ill patients
- • admission between 01.01.2020 and 31.12.2024 (5yrs)
- Exclusion Criteria:
- • none
About Charles University, Czech Republic
Charles University, located in the Czech Republic, is a prestigious institution renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive academic expertise and state-of-the-art facilities to conduct innovative research that aims to improve patient outcomes and contribute to the global medical community. With a focus on ethical standards and rigorous scientific methodologies, Charles University collaborates with various stakeholders to explore new therapies and enhance healthcare practices, fostering a culture of excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pilsen, , Czech Republic
Patients applied
Trial Officials
Thomas Karvunidis, MD, PhD
Principal Investigator
Faculty of Medicine and Teaching Hospital, Charles University, Pilsen, Czech Republic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported